Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05175274
PHASE3

Colchicine Use for Primary Prevention of Coronary Artery Disease

Sponsor: Qingdao Central Hospital

View on ClinicalTrials.gov

Summary

Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.

Official title: Colchicine Use for Primary Prevention in People at High Risk of Coronary Artery Disease

Key Details

Gender

All

Age Range

40 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

6792

Start Date

2022-12-06

Completion Date

2028-07-01

Last Updated

2022-03-21

Healthy Volunteers

No

Interventions

DRUG

Colchicine

Colchicine 0.5mg/tablet

DRUG

Placebo

matching placebo

Locations (1)

Mengmei Li

Qingdao, Shandong, China